[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2015001343A1 - Forma de dosificacion solida que comprende citisina micronizada y metodo de produccion. - Google Patents

Forma de dosificacion solida que comprende citisina micronizada y metodo de produccion.

Info

Publication number
CL2015001343A1
CL2015001343A1 CL2015001343A CL2015001343A CL2015001343A1 CL 2015001343 A1 CL2015001343 A1 CL 2015001343A1 CL 2015001343 A CL2015001343 A CL 2015001343A CL 2015001343 A CL2015001343 A CL 2015001343A CL 2015001343 A1 CL2015001343 A1 CL 2015001343A1
Authority
CL
Chile
Prior art keywords
citisine
micronized
dosage form
production method
solid dosage
Prior art date
Application number
CL2015001343A
Other languages
English (en)
Inventor
Hanna Wahl
Marek Dabrowa
Piotr Kulazinski
Original Assignee
Aflofarm Farmacja Polska Spolka Z Ograniczona Odpowiedzialnoscia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50730669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015001343(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aflofarm Farmacja Polska Spolka Z Ograniczona Odpowiedzialnoscia filed Critical Aflofarm Farmacja Polska Spolka Z Ograniczona Odpowiedzialnoscia
Publication of CL2015001343A1 publication Critical patent/CL2015001343A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMA DE DOSIS SOLIDA EN FORMA DE UNA CAPSULA DURA QUE CONTIENE CITISINA MICRONIZADA; Y METODO DE OBTENCION.
CL2015001343A 2012-11-19 2015-05-18 Forma de dosificacion solida que comprende citisina micronizada y metodo de produccion. CL2015001343A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL401676A PL220354B1 (pl) 2012-11-19 2012-11-19 Stała postać dawkowania zawierająca zmikronizowaną cytyzynę oraz sposób jej otrzymywania

Publications (1)

Publication Number Publication Date
CL2015001343A1 true CL2015001343A1 (es) 2015-10-23

Family

ID=50730669

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015001343A CL2015001343A1 (es) 2012-11-19 2015-05-18 Forma de dosificacion solida que comprende citisina micronizada y metodo de produccion.

Country Status (16)

Country Link
US (1) US9387172B2 (es)
EP (1) EP2919761B1 (es)
AU (1) AU2013346363B2 (es)
CL (1) CL2015001343A1 (es)
CY (1) CY1122947T1 (es)
DK (1) DK2919761T3 (es)
ES (1) ES2793527T3 (es)
HR (1) HRP20200642T1 (es)
HU (1) HUE048912T2 (es)
LT (1) LT2919761T (es)
NZ (1) NZ708199A (es)
PL (1) PL220354B1 (es)
PT (1) PT2919761T (es)
RS (1) RS60249B1 (es)
SI (1) SI2919761T1 (es)
WO (1) WO2014076680A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL408608A1 (pl) 2014-06-18 2015-12-21 Pharmacia Polonica Spółka Z Ograniczoną Odpowiedzialnością Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania
GB201602145D0 (en) * 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
CN111278826A (zh) * 2017-07-24 2020-06-12 英国雅琪制药有限公司 野靛碱盐
EP3598968A1 (en) 2018-07-23 2020-01-29 Adamed Pharma S.A. Solid pharmaceutical cytisine composition
BG67408B1 (bg) * 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости
PL444090A1 (pl) * 2023-03-16 2024-09-23 Uniwersytet Rzeszowski Polimerowe kompozycje z cytyzyną oraz sposób ich wytwarzania

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG65536B1 (bg) 2004-04-16 2008-11-28 "Софарма" Ад Лекарствена форма, съдържаща цитизин
US20060211649A1 (en) 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
AU2009303979A1 (en) 2008-10-14 2010-04-22 Mcneil Ab Multi portion intra-oral dosage form and use thereof
EP2233134A1 (en) 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties

Also Published As

Publication number Publication date
WO2014076680A1 (en) 2014-05-22
DK2919761T3 (da) 2020-11-02
EP2919761B1 (en) 2020-01-15
SI2919761T1 (sl) 2020-08-31
AU2013346363A1 (en) 2015-06-11
EP2919761A1 (en) 2015-09-23
AU2013346363B2 (en) 2018-08-09
RS60249B1 (sr) 2020-06-30
PT2919761T (pt) 2020-05-18
PL220354B1 (pl) 2015-10-30
US20150342884A1 (en) 2015-12-03
NZ708199A (en) 2018-10-26
LT2919761T (lt) 2020-05-25
CY1122947T1 (el) 2021-10-29
PL401676A1 (pl) 2014-05-26
HUE048912T2 (hu) 2020-08-28
ES2793527T3 (es) 2020-11-16
US9387172B2 (en) 2016-07-12
HRP20200642T1 (hr) 2020-09-04

Similar Documents

Publication Publication Date Title
CL2015001343A1 (es) Forma de dosificacion solida que comprende citisina micronizada y metodo de produccion.
PH12019500176A1 (en) Heterocyclic compounds and ther uses
EA201690246A1 (ru) Ингибиторы аутотаксинов, содержащие ядро гетероароматическое кольцо-бензил-амидный цикл
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
EA201400754A2 (ru) Новые фосфатные соединения, способ их получения и фармацевтические композиции, содержащие их
AR091700A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
BR112013028512A2 (pt) cápsula
ZA201508454B (en) Method of applying a composition and pharmaceutical composition with a regimen of administering it, including photo-activating the active component
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
BR112015023523B8 (pt) Composições farmacêuticas e recipiente de forma de dosagem única
MX2015008813A (es) Composiciones y metodos para contrarrestar la inhibicion del factor xa.
EA201491281A1 (ru) КОМПОЗИЦИЯ В ФОРМЕ СУХОГО ПОРОШКА, СОДЕРЖАЩАЯ КОРТИКОСТЕРОИД И β-АДРЕНЕРГИЧЕСКОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, ДЛЯ ВВЕДЕНИЯ ИНГАЛЯЦИЕЙ
MX2015012416A (es) Compuestos heterociclicos y sus usos.
ITUB20152179A1 (it) Gruppo di alimentazione per il dosaggio di compresse in capsule
CR20120494S (es) Empaque blister para producto
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
HK1218622A1 (zh) 含有改性瓜爾膠的藥物軟明膠膠囊劑型
IN2013MU01111A (es)
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación
HK1220113A1 (zh) 藥物軟明膠膠囊劑型
CL2016000397A1 (es) Tratamiento contra el cáncer
CL2016001062A1 (es) Composiciones y métodos para administración de una enzima a las vías respiratorias de un sujeto
HK1210723A1 (en) High dose extended-release potassium citrate wax matrix tablet
UY34769A (es) Forma farmacéutica oral para la prevención de enfermedades vasculares, comprimido como forma farmacéutica y cápsula gelatinosa como forma farmacéutica